Related Experiment Video
Updated: Nov 20, 2025

Probing Myosin Ensemble Mechanics in Actin Filament Bundles Using Optical Tweezers
Published on: May 4, 2022
Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin
Larry S Tobacman1, Anthony Cammarato2
1Departments of Medicine and of Physiology and Biophysics, University of Illinois at Chicago, Chicago, IL.
Insights
Mutations in cardiac troponin, the heart muscle
Area of Science:
- Muscle physiology
- Cardiovascular genetics
- Molecular biology
Background:
- Cardiac troponin is key to heart muscle contraction.
- Mutations in troponin genes cause hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy.
- Recent advances in structural biology provide new context for studying these mutations.
Purpose of the Study:
- To examine cardiomyopathy-inducing troponin mutations within the structural context of the thin filament.
- To gain new insights into the pathogenesis of cardiomyopathies and the troponin regulatory mechanism.
Main Methods:
- Compiled pathogenic troponin mutation sites from consortium reports.
- Compiled apparently tolerant mutation sites from the gnomAD v2 database.
- Analyzed mutation locations in relation to troponin's interaction with actin and tropomyosin.
Main Results:
- Pathogenic mutations cluster in troponin regions contacting actin/tropomyosin, including troponin I (CT) and troponin T (NT).
- Mutations are located in regions that inhibit contraction at low Ca2+ levels.
- Loss-of-function mutations in these regions correlate with HCM's hypercontractile phenotype.
- Pathogenic and benign mutations are rare in the Ca2+-binding troponin C N-lobe.
Conclusions:
- Cardiomyopathy mutations disrupt the Ca2+-dependent inhibition of muscle contraction.
- The structural location of mutations provides insight into HCM pathogenesis.
- The troponin C N-lobe appears intolerant to mutations, highlighting its critical role.
Abstract:
Reversible Ca2+ binding to troponin is the primary on-off switch of the contractile apparatus of striated muscles, including the heart. Dominant missense mutations in human cardiac troponin genes are among the causes of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. Structural understanding of troponin action has recently advanced considerably via electron microscopy and molecular dynamics studies of the thin filament. As a result, it is now possible to examine cardiomyopathy-inducing troponin mutations in thin-filament structural context, and from that to seek new insight into pathogenesis and into the troponin regulatory mechanism. We compiled from consortium reports a representative set of troponin mutation sites whose pathogenicity was determined using standardized clinical genetics criteria. Another set of sites, apparently tolerant of amino acid substitutions, was compiled from the gnomAD v2 database. Pathogenic substitutions occurred predominantly in the areas of troponin that contact actin or tropomyosin, including, but not limited to, two regions of newly proposed structure and long-known implication in cardiomyopathy: the C-terminal third of troponin I and a part of the troponin T N terminus. The pathogenic mutations were located in troponin regions that prevent contraction under low Ca2+ concentration conditions. These regions contribute to Ca2+-regulated steric hindrance of myosin by the combined effects of troponin and tropomyosin. Loss-of-function mutations within these parts of troponin result in loss of inhibition, consistent with the hypercontractile phenotype characteristic of HCM. Notably, pathogenic mutations are absent in our dataset from the Ca2+-binding, activation-producing troponin C (TnC) N-lobe, which controls contraction by a multi-faceted mechanism. Apparently benign mutations are also diminished in the TnC N-lobe, suggesting mutations are poorly tolerated in that critical domain.
Related Concept Videos
The Sarcomere
Each...
Actin and Myosin in Muscle Contraction
Actin Polymerization and Cell Motility
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate....
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Introduction to Actin
Cross-bridge Cycle

